Company Profile
Xeris Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- XERS
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Xeris Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
7.20 USD (+4.35%)
Close
Last updated: June 23, 2026 at 00:00
1.24B USD
Market cap
Why the stock is moving
XERS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Xeris Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Xeris Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Xeris Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Source: Xeris Pharmaceuticals
- 02
Xeris Biopharma Announces Private Exchange of Convertible Notes
Source: Xeris Pharmaceuticals
- 03
Xeris Biopharma Reports First Quarter 2026 Financial Results
Source: Xeris Pharmaceuticals
- 04
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Source: Xeris Pharmaceuticals
- 05
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Source: Xeris Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals (XERS) most recently closed at 7.20 USD, a +4.35% move versus the previous session.
What is the market cap of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals currently has a market capitalization of 1.24B USD on BioPharmSignal.
What does Xeris Pharmaceuticals do?
Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is XERS stock listed?
Xeris Pharmaceuticals (XERS) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Xeris Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Xeris?
Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Xeris Pharmaceuticals targeting with Xeris?
Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Pharmaceuticals?
Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.